A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
John E. Bateman
Chief Operating Officer
Dallas, Texas
11/14/2018
This Form 13F includes only the reportable 2,912,523 Class A shares of Reata Pharmaceuticals, Inc. ("Reata") over which CPMG, Inc. ("CPMG") had investment discretion as of September 30, 2018. This Form 13F does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of September 30, 2018 because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.